Anti-Parkinson's Drugs: Global Markets to 2022

Published - Apr 2018| Code - PHM193A| Analyst - BCC Research Reference Staff

Report Highlights

The global anti-Parkinson’s drugs market should reach $5.7 billion by 2022 from $4.2 billion in 2017 at a compound annual growth rate (CAGR) of 6.1% from 2017 to 2022.

Report Includes

  • 95 data tables
  • Country specific data and analysis for China, India, Japan, Australia, United Kingdom, Germany, France, Italy, Spain, Russia, USA, and Brazil
  • Analyses of the major factors and technological advances such as biomarkers, 3D printed drugs, mobile applications and wearable technologies in the monitoring and treatment of Parkinson’s disease
  • Discussion of the major segments of the anti-Parkinson’s drugs, i.e., dopaminergic drugs, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications
  • Company profiles of the major players in the market, including AbbVie, Mylan Laboratories, Valeant Pharmaceuticals and Novartis

Report Scope 

This research report categorizes the anti-Parkinson’s drugs market by type. Product types include low dopaminergic, dopamine agonists, enzyme inhibitors and other anti-Parkinson’s medications.

Analyst Credentials

BCC Research analysts craft reference reports with a unique end noted referencing methodology, which allows users to cross reference and trace market numbers back to their source. These individuals are experts in secondary research and primary forecasting - compiling and layering existing data with their original research and analysis. The team has decades of combined experience covering a wide range of industries, including healthcare, advanced materials and emerging technologies

Table of Contents & Pricing

All reports provided in PDF format. For shared licensing options (5+ Users), please call a representative at (+1) 781-489-7301 or contact us at info@bccresearch.com
Note: Reports are discounted or included with certain Memberships. See Membership Options.
Title/Chapter Name Pages Price Member Price
Full Report: Anti-Parkinson's Drugs: Global Markets to 2022 172 $5,500 Free
Chapter- 1: Introduction4Free DownloadFree
Chapter- 2: Summary and Highlights2$250Free
Chapter- 3: Anti-Parkinson's Drugs Market Characteristics2$65Free
Chapter- 4: Anti-Parkinson's Drugs Market Size and Growth5$162Free
Chapter- 5: Anti-Parkinson's Drugs Market Trends and Strategies2$65Free
Chapter- 6: PESTLE Analysis9$291Free
Chapter- 7: Anti-Parkinson's Drugs Market Segmentation7$226Free
Chapter- 8: Anti-Parkinson's Drugs Market Regional and Country Analysis10$324Free
Chapter- 9: Global Anti-Parkinson's Drugs Market Comparison with Macro Economic Factors2$65Free
Chapter- 10: Asia-Pacific Anti-Parkinson's Drugs Market8$259Free
Chapter- 11: Asia-Pacific Anti-Parkinson's Drugs Market: Country Analysis24$776Free
Chapter- 12: Western Europe Anti-Parkinson's Drugs Market8$259Free
Chapter- 13: Western Europe Anti-Parkinson's Drugs Market: Country Analysis23$744Free
Chapter- 14: Eastern Europe Anti-Parkinson's Drugs Market7$226Free
Chapter- 15: Eastern Europe Anti-Parkinson's Drugs Market: Country Analysis5$162Free
Chapter- 16: North America Anti-Parkinson's Drugs Market8$259Free
Chapter- 17: North America Anti-Parkinson's Drugs Market: Country Analysis5$162Free
Chapter- 18: South America Anti-Parkinson's Drugs Market7$226Free
Chapter- 19: South America Anti-Parkinson's Drugs Market: Country Analysis5$162Free
Chapter- 20: Middle East Anti-Parkinson's Drugs Market7$226Free
Chapter- 21: Africa Anti-Parkinson's Drugs Market6$194Free
Chapter- 22: Anti-Parkinson's Drugs Market Customer Information2$65Free
Chapter- 23: Anti-Parkinson's Drugs Market Competitive Landscape11$356Free
Chapter- 24: Key Mergers and Acquisitions in the Anti-Parkinson's Drugs Market1$32Free
Chapter- 25: Appendix2$65Free
 
RELATED REPORTS
Share This Report